Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Saint Paul Press.
Press releases published on July 28, 2025

Veteran-Turned-Author Shares Candid Story of Addiction, Redemption, and Faith in New Memoir
Ryan's new book, God Only Knows When the Devil Comes for You, offers readers a raw, faith-filled account of overcoming trauma, addiction, and personal loss. MINNEAPOLIS, MN, UNITED STATES, July 28, 2025 /EINPresswire.com/ -- In a newly released memoir, …

Dr. Janine Bremer of Gravon's Natural Chiropractic Center Shares Insights as Migraine Treatment Expert in HelloNation
What causes recurring migraines even when medications fall short? WORTHINGTON, MN, UNITED STATES, July 28, 2025 /EINPresswire.com/ -- What causes recurring migraines even when medications fall short? In a HelloNation article, Dr. Janine Bremer of Gravon …

Jobma Wins SourceForge Summer 2025 Top Performer Award
Jobma has been named the Summer 2025 Top Performer in the video interviewing software category. MINNETONKA, MN, UNITED STATES, July 28, 2025 /EINPresswire.com/ -- Jobma, a leading AI video interviewing and assessment platform, announced that it has been …

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
MINNEAPOLIS, July 28, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced proposed underwritten public offerings of $150,000, …

Fielo expands B2B commerce loyalty capabilities to help global enterprises accelerate retention and revenue
Built on Salesforce, Fielo’s platform gives B2B brands the tools to drive repeat purchases, grow customer lifetime value, and deepen buyer relationships MINNEAPOLIS, MN, UNITED STATES, July 27, 2025 /EINPresswire.com/ -- As global B2B enterprises face …

Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial
Hazard Ratios and Improvements in Median PFS are Unprecedented in HR+/HER2- Advanced Breast Cancer (“ABC”) Gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) reduced the risk of disease progression or death by 76% vs. fulvestrant (HR=0.24; 95% …